AR-V7 in Castration Resistant Prostate Cancer
Dr. Emmanuel Antonarakis discusses treating chemo-naive metastatic hormone-sensitive prostate cancer and then discusses the impact of AR-V7 in CRPC.
Read MoreSelect Page
Posted by Emmanuel S. Antonarakis, MD | Mar 2018
Dr. Emmanuel Antonarakis discusses treating chemo-naive metastatic hormone-sensitive prostate cancer and then discusses the impact of AR-V7 in CRPC.
Read MorePosted by Brian J. Moran, MD | Mar 2018
Brian Moran, MD, discusses focal brachytherapy, stereotactic transperineal prostate biopsy (STPB),...
Read MorePosted by Maha H. Hussain, MD, FACP, FASCO | Mar 2018
Dr. Maha H.A. Hussain, MBChB, reviews the PROSPER trial, which tested the efficacy and safety of enzalutamide in the setting of nonmetastatic CRPC. Following her summary, she and Dr. E. David Crawford, MD, engage in a question and answer session.
Read MorePosted by Jack A. Schalken, PhD | Feb 2018
Jack A Schalken, PhD, and E. David Crawford, MD, discuss recent advances in non invasive liquid...
Read MorePosted by Scott T. Tagawa, MD | Feb 2018
Scott T. Tagawa, MD, Weill Cornell Medicine, provides an overview of radiogland therapy and...
Read More